Table 2. Distribution of initial dose, median dose, dose modification, and reason for treatment discontinuation.
| eGFR, mL/min/1.73 m2 | |||
|---|---|---|---|
| Variables | <45 | ≥45 | P-value |
| (n = 613) | (n = 613) | ||
| Mean starting dose, mg/day | 687.1 ± 192.1 | 726.3 ± 159.8 | 0.0001 |
| Median daily dose, mg/day | 484.4 [388.5] | 481.0 [415.5] | 0.3181 |
| Relative dose intensity, % | 65.7 ± 26.5 | 67.2 ± 26.5 | 0.3197 |
| Median duration of treatment, mo | 6.11 [10.22] | 6.60 [9.72] | 0.2944 |
| Dose modification | |||
| Reduction | 357 (58.2) | 360 (58.7) | 0.862 |
| Interruption | 269 (43.9) | 263 (42.9) | 0.7295 |
| Discontinuation | 429 (70.0) | 428 (69.8) | 0.9504 |
| Reason for discontinuation | |||
| Adverse events | 264 (61.5) | 244 (57.0) | 0.1772 |
| Insufficient effect | 130 (30.3) | 142 (33.2) | 0.366 |
Data are presented as mean ± standard deviation, median [interquartile range], or n (%).
Abbreviations: AE = adverse event; eGFR = estimated glomerular filtration rate.